Czech Republic-based SCTbio, a cGMP manufacturing services for cell-based products, today announced a strategic partnership with Sweden’s CCRM Nordic, an organization dedicated to accelerating the commercialization of regenerative medicine technologies and cell and gene therapies.
The companies note that this collaboration coincides with a pivotal time for the cell and gene therapy industry, as the sector faces several challenges that put focus and demand on driving efficiency in development pathways. With increasing regulatory approvals and the first treatment for solid tumours approved, there is growing clinical evidence supporting advanced therapies, which shows promise for the future of these new technologies.
However, challenges remain in scaling production and controlling costs. The partnership will combine SCTbio's expertise in cGMP manufacturing with CCRM Nordic's comprehensive infrastructure and analytical capabilities to provide end-to-end support for early-stage cell therapy companies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze